Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases

Area of Science:

• Oncology
• Neuro-oncology
• Molecular Biology

Background:

• Small cell lung cancer (SCLC) frequently metastasizes to the brain, leading to a poor prognosis.
• SCLC can be subtyped based on the expression of transcriptional factors ASCL1 and NEUROD1.

Purpose of the Study:

• To investigate the impact of SCLC subtypes, defined by ASCL1 and NEUROD1 expression, on the incidence and outcomes of brain metastases (BMs).

Main Methods:

• Classified 164 SCLC patients into four subtypes based on ASCL1 and NEUROD1 immunohistochemical expression: A+/N-, A+/N+, A-/N+, and A-/N-.
• Utilized cumulative incidence competing risk analyses for CNS progression and Cox proportional hazards models for overall survival (OS) and CNS progression-free survival (CNS-PFS).

Main Results:

• The A+/N- subtype showed a numerically highest 12-month cumulative incidence of subsequent CNS progression (50%) among patients with BMs at diagnosis.
• Among BM-free patients at diagnosis, A+/N- (16%) and A-/N+ (9.1%) subtypes had the numerically highest 12-month cumulative incidence of CNS progression.
• Both A+/N- (HR, 1.62) and A-/N+ (HR, 3.02) subtypes exhibited significantly worse OS compared to the A+/N+ subtype.
• Patients receiving CNS-directed radiotherapy demonstrated superior response rates (65% CR/PR) compared to those receiving systemic therapy alone (36% CR/PR).

Conclusions:

• This study is the first to link SCLC transcription factor subtypes to CNS-specific outcomes.
• SCLC patients who were BM-free at diagnosis and belonged to the A+/N- or A-/N+ subtypes experienced worse outcomes than those with coexpression.
• Further research into SCLC subtyping mechanisms is crucial for developing personalized treatment strategies for CNS-specific care.